These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20566370)

  • 1. Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors.
    Liu M; Poulose S; Schuman E; Zaitsev AD; Dobson B; Auerbach K; Seyb K; Cuny GD; Glicksman MA; Stein RL; Yue Z
    Anal Biochem; 2010 Sep; 404(2):186-92. PubMed ID: 20566370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities.
    Liu M; Dobson B; Glicksman MA; Yue Z; Stein RL
    Biochemistry; 2010 Mar; 49(9):2008-17. PubMed ID: 20146535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a high-throughput AlphaScreen assay measuring full-length LRRK2(G2019S) kinase activity using moesin protein substrate.
    Pedro L; Padrós J; Beaudet L; Schubert HD; Gillardon F; Dahan S
    Anal Biochem; 2010 Sep; 404(1):45-51. PubMed ID: 20434426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.
    Liu Z; Galemmo RA; Fraser KB; Moehle MS; Sen S; Volpicelli-Daley LA; DeLucas LJ; Ross LJ; Valiyaveettil J; Moukha-Chafiq O; Pathak AK; Ananthan S; Kezar H; White EL; Gupta V; Maddry JA; Suto MJ; West AB
    J Biol Chem; 2014 Nov; 289(47):32937-51. PubMed ID: 25228699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.
    Hermanson SB; Carlson CB; Riddle SM; Zhao J; Vogel KW; Nichols RJ; Bi K
    PLoS One; 2012; 7(8):e43580. PubMed ID: 22952710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.
    Leveridge M; Collier L; Edge C; Hardwicke P; Leavens B; Ratcliffe S; Rees M; Stasi LP; Nadin A; Reith AD
    J Biomol Screen; 2016 Feb; 21(2):145-55. PubMed ID: 26403521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.
    Reichling LJ; Riddle SM
    Biochem Biophys Res Commun; 2009 Jun; 384(2):255-8. PubMed ID: 19397894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?
    Gillardon F; Kremmer E; Froehlich T; Ueffing M; Hengerer B; Gloeckner CJ
    J Neurosci Methods; 2013 Mar; 214(1):62-8. PubMed ID: 23318290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition.
    Covy JP; Giasson BI
    J Neurochem; 2010 Oct; 115(1):36-46. PubMed ID: 20626563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.
    Liu M; Bender SA; Cuny GD; Sherman W; Glicksman M; Ray SS
    Biochemistry; 2013 Mar; 52(10):1725-36. PubMed ID: 23379419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A continuous and direct assay to monitor leucine-rich repeat kinase 2 activity.
    Silva RG; Geoghegan KF; Qiu X; Aulabaugh A
    Anal Biochem; 2014 Apr; 450():63-9. PubMed ID: 24463014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking.
    Lang CA; Ray SS; Liu M; Singh AK; Cuny GD
    Bioorg Med Chem Lett; 2015 Jul; 25(13):2713-9. PubMed ID: 25998502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.
    Göring S; Taymans JM; Baekelandt V; Schmidt B
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4630-4637. PubMed ID: 25219901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant.
    Liu M; Kang S; Ray S; Jackson J; Zaitsev AD; Gerber SA; Cuny GD; Glicksman MA
    Biochemistry; 2011 Nov; 50(43):9399-408. PubMed ID: 21961647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.
    Garofalo AW; Adler M; Aubele DL; Brigham EF; Chian D; Franzini M; Goldbach E; Kwong GT; Motter R; Probst GD; Quinn KP; Ruslim L; Sham HL; Tam D; Tanaka P; Truong AP; Ye XM; Ren Z
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1974-7. PubMed ID: 23453068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity.
    Ray S; Bender S; Kang S; Lin R; Glicksman MA; Liu M
    J Biol Chem; 2014 May; 289(19):13042-53. PubMed ID: 24695735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiplexed random peptide library and phospho-specific antibodies facilitate human polo-like kinase 1 inhibitor screen.
    Tanaka K; Koresawa M; Iida M; Fukasawa K; Stec E; Cassaday J; Chase P; Rickert K; Hodder P; Takagi T; Komatani H
    Assay Drug Dev Technol; 2010 Feb; 8(1):47-62. PubMed ID: 20085455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro.
    Liu Z; West AB
    Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):274-280. PubMed ID: 27939437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.
    Reith AD; Bamborough P; Jandu K; Andreotti D; Mensah L; Dossang P; Choi HG; Deng X; Zhang J; Alessi DR; Gray NS
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5625-9. PubMed ID: 22863203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
    Deng X; Choi HG; Buhrlage SJ; Gray NS
    Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.